News >

Role of MRD Still Evolving Across Hematologic Cancers

Jessica Hergert
Published: Thursday, Oct 10, 2019

Imad Tabbara, MD

Imad Tabbara, MD

Novel therapeutic advances in multiple myeloma, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML) have led to a rapid evolution of disease management, which has increased the focus on the appropriate role of minimal residual disease (MRD) as a prognosis predictor, said Imad Tabbara, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication